Clinical Analysis of Heparin‐Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation
Seminars in Dialysis · 2025
DOI: 10.1111/sdi.13259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Dialysis, 2025. Verfasst von Chenling Lv und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Heparin, Thrombocytopenia, Anticoagulants, Plasmapheresis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Beijing Municipal Hospital Scientific Research and Cultivation Project.
Abstract (Originalsprache)
Objective
We investigated the clinical characteristics and treatment outcomes of heparin‐induced thrombocytopenia (HIT) following therapeutic plasma exchange (TPE) with heparin anticoagulation in patients with neurological autoimmune diseases.
Methods
Clinical data were prospectively collected from 158 patients (79 males, 79 females; mean age 37.49 ± 16.95 years) with neurological autoimmune diseases who underwent TPE in the neuro‐intensive care unit between January 2016 and June 2024. For patients with continuous platelet decline after TPE, the 4Ts score was determined, and platelet factor 4 (PF4) antibody tests were performed. Their platelet counts, clinical complications (thrombosis and bleeding), treatment plans, outcomes, and prognoses before and after TPE were analyzed.
Results
One hundred thirty‐nine patients experienced at least one significant decrease in platelet count during TPE (average decrease 36.75 ± 19.63%), and the average 4Ts score was 3.55 ± 1.87 points. PF4 antibody testing was conducted on 23 patients with continuous platelet decline and 4Ts scores ≥ 4. Four PF4‐positive patients were diagnosed with type II HIT and developed deep vein thrombosis. After heparin withdrawal, the platelet count gradually normalized after intravenous immunoglobulin (IVIG), nonheparin TPE, or argatroban/fondaparinux anticoagulant therapy (mean recovery time 8.17 ± 3.54 days). The platelet counts spontaneously recovered for the remaining 116 patients (mean recovery time 3.88 ± 2.66 days).
Conclusion
Platelet counts should be dynamically monitored throughout TPE with heparin anticoagulation. Patients with continually decreasing platelet counts and an intermediate to high 4Ts score should be monitored for HIT. Heparin should be discontinued immediately for patients with type II HIT, and nonheparin anticoagulants, IVIG, or nonheparin TPE may be administered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of Neurology, Tongde Hosiptal of Zhejiang Province, Hangzhou, China.
- Department of Neurology, Chongqing Hechuan District People's Hospital, Chongqing, China.
ORCID-Profile: Chenling Lv
Förderung
- Beijing Municipal Hospital Scientific Research and Cultivation Project
Zitieren
APA
Lv, C., Liang, H., Tian, F., Liu, G., Chen, W., & Zhang, Y. (2025). Clinical Analysis of Heparin‐Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation. Seminars in Dialysis. https://doi.org/10.1111/sdi.13259
Vancouver
Lv C, Liang H, Tian F, Liu G, Chen W, Zhang Y. Clinical Analysis of Heparin‐Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation. Seminars in Dialysis. 2025. doi:10.1111/sdi.13259
BibTeX
@article{Lv2025,
author = {Lv, Chenling and Liang, Hongtao and Tian, Fei and Liu, Gang and Chen, Weibi and Zhang, Yan},
title = {Clinical Analysis of Heparin‐Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation},
journal = {Seminars in Dialysis},
year = {2025},
doi = {10.1111/sdi.13259}
}
EUVIMED